Recognising and managing diabetic retinopathy by Hall, Anthony
   Community EyE HEaltH Journal | Vol 24 iSSuE 75 | SEPtEmBEr 2011  5
DIAGnOSIS	AnD	MAnAGEMEnT
Recognising and managing 
diabetic retinopathy
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Key	learning	points	
•	Detecting and diagnosing diabetic retinopathy is not 
complicated. There are clinical signs which can be seen with 
an ophthalmoscope or a slit lamp and 90- or 78-dioptre lens.
•	Diabetic retinopathy is treatable. Treatment usually maintains 
vision, but does not restore vision that has alread y been lost. 
•	In diabetic maculopathy, laser or anti-VEGF injections are 
both proven to work. Intravitreal steroid is ineffective in 
most patients.
•	Laser treatment should use small spots and just enough 
power to produce a visible reaction.
•	Proliferative retinopathy is best treated with pan-retinal laser. 
The commonest error is undertreatment, and laser should be 
applied until there is regression of the new vessels or there is 
no room for further treatment.
•	Vitrectomy is useful for vitreous haemorrhage and late 
complications of proliferative retinopathy. Pre-treatment 
with bevacizumab reduces the risk of surgical complications.
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Figure 4. New vessels, the key 
characteristic of proliferative diabetic 
retinopathy 
Figure 5. Pre-retinal haemorrhage, one of 
the signs of proliferative diabetic 
retinopathy 
Figure 1. Haemorrhages (larger, uneven 
red ‘blots’) and microaneurysms (small, 
round ‘dots’)
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Figure 2. Venous beading, i.e., irregular 
calibre (‘thickness’) of the veins
U
n
i
v
e
r
s
i
t
y
 
o
f
 
W
i
s
c
o
n
s
i
n
 
F
u
n
d
u
s
 
P
h
o
t
o
g
r
a
p
h
 
R
e
a
d
i
n
g
 
C
e
n
t
e
r
a
Figure 3. Intraretinal microvascular 
abnormalities (IRMA). The circles show 
the odd, twisted shape of IRMA
The clinical signs of proliferative Dr 
include: 
•	new vessels growing onto the posterior 
vitreous surface from the retina or optic 
disc (Figure 4)
•	vitreous and/or pre-retinal 
haemorrhages (Figure 5)
•	fibrosis 
•	traction retinal detachment.
Continues overleaf ➤
Recognising	DR
The management of diabetic retinopathy 
(DR) depends on accurately recog-
nising or classifying the different types 
of DR and knowing what treatment to 
give the patient.
DR has clinical signs which can be 
seen with an ophthalmoscope or with a 
slit lamp and a 90- or 78-dioptre lens. 
The advantage of the slit lamp is that it 
allows you to visualise the retina with both 
eyes. This stereoscopic vision provides a 
sense of depth which aids diagnosis, 
particularly of macular oedema. Other 
aids to DR diagnosis are fundus photog-
raphy, fluorescein angiography, and 
optical coherence tomography (see box 
on page 7).
1	non-proliferative	DR
The clinical signs of non-proliferative Dr 
are:
•	haemorrhages (Figure 1)
•	microaneurysms (Figure 1)
•	venous beading (Figure 2)
•	intraretinal microvascular abnormalities 
(IRMA) (Figure 3)
2	Proliferative	DR	
Proliferative DR can exhibit all the same 
clinical signs as non-proliferative DR. 
However, the key characteristic of 
proliferative DR is new vessels growing 
onto the posterior vitreous surface from 
the retina or optic disc (Figure 4).
The new vessels damage sight by 
bleeding (Figure 5) or forming sheets of 
fibrovascular membranes that may 
cause traction retinal detachments. 
Traction retinal detachment occurs when 
the fibrovascular tissue contracts and 
pulls the retina away from the underlying 
choroid. If this affects the macula, the 
central vision will be lost. 
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3	Diabetic	maculopathy
Diabetic maculopathy occurs when
DR affects the central part of the
retina. Blood vessels leak, leading to 
diabetic macular oedema (swelling
of the retina).  
The early treatment of diabetic
retinopathy study (ETDRS) defi  ned
clinically signifi  cant macular oedema 
(CSMO)1 as the stage at which the eye 
needs to be treated in order to prevent 
loss of vision. The defi  nition depends on 
recognising the following:
•	retinal thickening and exudates (Figure 6) 
at or within 500 microns of the fovea 
(within one third of a disc diameter).
•	larger zones of retinal thickening (one 
disc diameter or more), if within one 
disc diameter of the fovea. 
Retinal thickening can only be observed 
stereoscopically. So, for practical clinical 
purposes, look for other easily visible 
markers for macular oedema such as 
exudates within a disk diameter of the fovea.
The blood vessels in the central part of 
the retina may also become blocked 
(capillary closure), leading to macular 
ischaemia. Macular ischaemia occurs 
when there is insuffi  cient blood supply
to the macula. This will impair the 
normal functioning of the retina, leading 
to reduced vision.
There is no effective treatment for 
macular ischaemia,1 but it is important 
to recognise it so that you don’t waste 
the patient’s time and money with 
ineffective laser or anti-vascular 
endothelial growth factor (anti-VEGF) 
treatment.
Although macular ischaemia
can only be diagnosed conclusively by 
fl  uorescein angiography (see box on
page 7), you should suspect it if the 
following conditions are met:
•	reduced visual acuity
•	evidence of retinal ischaemia, e.g. 
cotton wool spots (Figure 7) or blot 
haemorrhages
•	no macular oedema at the fovea
•	no other cause for reduced vision (e.g. 
cataract, refractive error).
Treating	proliferative	
diabetic	retinopathy
The two main treatment options for
proliferative DR are pan-retinal laser 
photocoagulation and diabetic vitrectomy.   
Pan-retinal	photocoagulation	(PRP)
Pan-retinal photocoagulation (PRP),
or scatter laser, is the main form of 
treatment for proliferative diabetic retin-
opathy.
The aim of the laser is to induce 
regression of new blood vessels (that is, 
to make them stop growing and shrink).
It must be given early enough and cover 
enough retina to induce regression of the 
vessels that cause the complications of 
vitreous haemorrhage and tractional 
detachment of the retina.
A 50% reduction in severe visual loss 
after PRP was reported by the Diabetic 
Retinopathy Study for patients with new 
vessels on the optic disc.1
Diabetic	vitrectomy	
Vitrectomy is indicated in proliferative 
diabetic retinopathy in the following 
conditions:
How I look for diabetic
 retinopathy: a vision
   technician’s experience
FROM	THE	FIELD
How I look for diabetic
 retinopathy: a vision
   technician’s experience
FROM	THE	FIELD
Figure 6. Exudates. This is an example of 
circinate exudates, which are circular in 
appearance
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Figure 7. Cotton wool spots
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spots
“I am Lalitha Y, 
and I have 
been working 
as a vision technician at LV Prasad Eye 
Institute since 2008. I hail from a 
remote rural village in Prakasham 
District and I joined the vision 
technician programme at LVPEI in 
2007. During this programme, we 
were trained to look for 
diabetic retinopathy (DR) 
by direct ophthalmo-
scope. 
“Whenever someone 
with diabetes visits my 
vision centre, I will 
initially take a detailed 
history regarding the duration of 
diabetes, their blood sugar control, 
medication (drugs/insulin), diet, 
physical activity, smoking, alcohol 
intake, family history of diabetes, and 
other systemic diseases like hyper-
tension, diabetic nephropathy, 
neuropathy, and so on. I also record 
any history of blurred vision for 
distance or near vision, fl  ashes, 
fl  oaters in the fi  eld of view, and any 
fl  uctuations in vision.
“After checking the patient’s visual 
acuity, I check for any extra-ocular 
muscle imbalance by checking eye 
movements in all directions. During a 
slit lamp examination (before dilation)
I look mainly for neovascularisation of 
the iris and record intraocular pressure.
“After dilation, I will then examine the 
posterior segment by direct ophthalmo-
scope. If the media are clear, I will check 
for signs of DR, such as haemorrhages 
or exudates. If the media are not clear 
or if the patient has signs of DR, I will 
refer the patient to a secondary centre 
ophthalmologist for 
dilated fundus exami-
nation, which will give 
them the information they 
need to manage the 
patient’s DR. Recently, I 
was trained to take fundus 
photographs. This helps 
me to identify patients with DR, who I 
would then send to a secondary centre 
for further management. 
“I will then talk to the patient and 
explain the role of good blood sugar 
control.”
Editor’s note: In patients with high 
blood pressure, good blood pressure 
control will reduce the likelihood that 
a patient’s DR will get worse (see 
article on page 4). Eye care workers 
would do well to check their patients’ 
blood pressure and advise those with 
high blood pressure on the importance 
of control, referring them to a physician 
if they needed help.
‘I will initially 
take a detailed 
patient history’
CEHJ75_OA.indd   6 25/10/2011   18:32   Community EyE HEaltH Journal | Vol 24 iSSuE 75 | SEPtEmBEr 2011  7
•	non-clearing vitreous haemorrhage
•	pre-retinal (or sub-hyaloid) 
haemorrhage
•	tractional retinal detachment 
threatening, or involving, the macula
•	combined rhegmatogenous/tractional 
detachment
•	progressive severe fibrovascular 
proliferation in spite of adequate PRP . 
Currently, vitrectomy for diabetic macular 
oedema is reserved for the few patients 
who have vitreous traction on the 
macula.2
The technique is an important part of 
the treatment of proliferative diabetic 
retinopathy and leads to improvement or 
stabilisation of vision in 90% of 
patients.1,2 Vitreous and blood are cut 
and aspirated and membranes causing 
tractional detachment of the retina are 
removed. This may be done by segmenting 
the membranes or by delamination, 
i.e. removing the whole of the posterior 
hyaloid and associated fibrovascular 
membranes by cutting them off the 
surface of the retina. 
In countries without screening, many 
people present with long-standing 
tractional retinal detachments of the 
macula. The result of diabetic vitrectomy 
in these eyes is not so good. In a 
resource-poor environment, those with a 
better prognosis should be prioritised. 
It is worth pre-treating patients with 
intravitreal bevacizumab prior to 
vitrectomy.3 A Cochrane review of six 
randomised controlled trials found that 
pre-treatment with 1.25 mg of intrav-
itreal bevacizumab resulted in shorter 
operations with less endodiathermy and 
intra-operative bleeding. Post-operative 
reabsorption of blood was significantly 
shorter. Final best-corrected visual acuity 
was significantly better. 
The effect of intravitreal bevacizumab 
on neovascularisation is rapid. The first 
effects can be seen in 24 hours. The 
optimum time for a preoperative injection 
would seem to be 5–7 days before the 
operation.
In a proportion of patients, intravitreal 
bevacizumab preoperatively may lead to 
clearing of the vitreous haemorrhage, 
thus avoiding surgery. 
Treating	diabetic	
maculopathy
Diabetic maculopathy is a major cause of 
vision loss amongst patients with 
diabetes. Treatment includes steroids, 
anti-vascular endothelial growth factor 
(anti-VEGF), and laser.
Steroid	treatments
In the Diabetic Retinopathy Clinical 
Research Network trial, intravitreal injec-
tions of the steroid triamcinolone 
acetonide was compared with standard 
laser treatment. Although there were 
short-term improvements in visual acuity 
with intravitreal triamcinolone acetonide 
(IVTA), this improvement was not 
sustained. Laser was more effective and 
had fewer side effects than IVTA. The side 
effects of IVTA included cataract 
formation and raised intraocular pressure. 
Recently, the same group found that 
there was one exception. In pseudo-
phakic eyes, IVTA and prompt laser 
seemed more effective than laser alone.4 
Anti-vascular	endothelial	growth	
factor	(anti-VEGF)	treatment
VEGF levels are increased in the 
vitreous and retina in patients with 
diabetic retinopathy. The most recent 
anti-VEGF drugs to be evaluated in the 
Continues overleaf ➤
Diabetic retinopathy (DR) can be 
diagnosed by clinical examination 
alone if you are good at examining 
the retina with a slit lamp micro-
scope. Using the slit lamp, you will be 
able to detect haemorrhages, new 
vessels, exudates, and retinal thick-
ening due to oedema. If the diagnosis 
can be made clinically, are investiga-
tions ever necessary?
Photos are 
probably the most 
useful investigation. 
The cost of fundus 
cameras is still high, 
but they are 
becoming more 
affordable and the 
quality of pictures is 
improving all the time. They are also 
easy to use. The most valuable use of 
photography is in patients with diabetic 
maculopathy or new vessels who have 
laser treatment. Often, the laser leads 
to a complete cure and the exudates 
and new vessels disappear. However, 
sometimes they do not completely 
resolve. If you only examine the patient 
occasionally, it is difficult to remember 
exactly what the retina looked like 
before you treated it. When you can 
still see retinopathy months after laser 
treatment, you may be unsure if it is 
better, worse, or much the same. If you 
have photos to refer to, you can be 
certain of what has changed. Of 
course, photos are also very useful for 
detecting DR and counselling patients. 
Fluorescein angiography is a 
technique for examining the fine detail 
of the retinal circulation. It will show 
the leaks that cause exudative 
maculopathy and the areas of blocked 
capillaries that cause ischaemic 
maculopathy and proliferative retin-
opathy. However, injections of 
fluorescein carry a small risk (about 
1:20,000) of a 
severe allergic 
response, which can 
be fatal. They should 
not be given unless 
there are facilities for 
resuscitation. 
optical 
coherence tomog-
raphy (oCt) is a relatively new 
technique that uses lasers to scan the 
retina and build up a very detailed 
three-dimensional image. This will not 
only detect any oedema or swelling of 
the retina, but also measure it and 
draw a map that shows the areas 
where the swelling is greatest. It is 
fast, safe, and does not require any 
injections. Unfortunately, the machines 
cost about £50,000! In high-income 
countries, OCT and photos, in combi-
nation, are the usual means of 
documenting and investigating DR. 
As cameras and OCT machines 
become more affordable, they will also 
become more widely used in low- and 
middle income countries.
Investigating DR: photos, fluorescein angiography and OCT
‘If you have photos 
to refer to, you can 
be certain of what 
has changed’
an optical coherence 
tomography (oCt) image of 
cystoid macular oedema
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treatment of diabetic maculopathy are 
ranibizumab2 (Lucentis) and bevaci-
zumab5 (Avastin). These trials showed a 
benefi  t with intravitreal ranibizumab and 
bevacizumab in patients with foveal 
thickening. However, intravitreal ranibi-
zumab injections cost around US $1,200 
each and the patients in this study 
received eight or nine injections in the 
fi  rst year (a cost of around US $10,000 
per patient per year.) Intravitreal
bevacizumab is much cheaper. We are 
able to offer patients an intravitreal 
bevacizumab injection for as little
as US $25. 
In practice, laser should remain the 
cornerstone of treating clinically signif-
icant macular oedema and the use of 
intravitreal injections should be tailored 
to the needs of individual patients.
Laser
The Early Treatment of Diabetic Retinopathy 
study compared macular laser with obser-
vation. There was a 50% reduction in 
moderate visual loss in the group that 
received laser (from 24% to 12%).
The recommended protocol is as follows: 
•	Treat circinate exudates (Figure 6) with 
focal laser, blanching the retina in the 
DIAGnOSIS	AnD	MAnAGEMEnT	Continued
Managing diabetic retinopathy in Africa
Case	study
In our clinic, a typical patient, Mrs X, was 
fi  rst seen with a visual acuity of 6/9, a 
few macular exudates, and proliferative 
disease. The treatment plan followed the 
textbook recommendation of doing focal 
laser for the maculopathy fi  rst. The 
patient then missed two appointments 
and pan-retinal photocoagulation (PRP) 
was delayed by about two months. When 
PRP was fi  nally given, the intention was 
to give it in the recommended multiple 
sessions. However, due to further missed 
appointments, the interval between laser 
sessions was over a month. This allowed 
fi  brovascular proliferation to continue. It 
was six months from the time of presen-
tation before laser was completed. By 
then, tractional retinal detachment 
involving the macula had developed and 
vitrectomy was required. Mrs X’s fi  nal 
visual acuity was counting fi  ngers at 
three metres.
What are the lessons to be learned 
from this? How can we do better?
We audited a number of patients who 
had ultimately needed vitrectomy for 
advanced proliferative disease to fi  nd out 
how we could improve, and arrived at the 
following recommendations 
for laser in countries where 
patients may not come for 
regular appointments.
Recommendations
1 Warn all diabetes 
patients to come if 
they experience 
ﬂ  oaters or blur, 
as these symptoms 
suggest a vitreous 
haemorrhage.
2 Give PrP to 
anyone who has 
vitreous or 
sub-hyaloid blood 
(Figure 5) even if 
there are no visible 
new vessels. Treat 
any size area of 
defi  nite neovascu-
larisation, on the 
disc or elsewhere. 
Treat any eye that has evidence of 
fi  brosis, as this is evidence of prolifer-
ative disease.
3 treat patients faster. Regression of 
new vessels should be seen after a 
week or two. (Figures 8 and 9). If 
patients come from far away, consider 
admitting them to complete the laser 
before they are discharged. Attempt to 
complete the laser in one week, 
instead of several weeks. Treat the 
inferior retina fi  rst as new blood falls 
down and blocks the view inferiorly.
4 make the most of each session 
you have. It is worth treating some 
patients in one session. This is partic-
ularly important if there are large 
neovascular (NV) formations which 
have an increased risk of bleeding, or 
if the patient is unlikely to return. 
Remember to avoid application of 
intense burns which are unnecessary 
to induce regression. A pan-retinal 
pattern of excessively intense 
burns can lead to choroidal 
effusion and angle-closure 
glaucoma with blindness. Treat 
one burn width apart, as shown 
in Figure 10. Oedema 
surrounding the burns makes 
them look more confl  uent than 
they are.
5 repeat treatment. 
All neovascularisation 
should regress in two 
to four weeks. If it has 
not regressed, treat 
again. If bleeding 
occurs after laser, 
re-treat until NV 
formations have gone 
or maximal treatment 
has been given. Consider 
treating inside the 
arcades, particularly 
temporally.
Figure 8. Eye before treatment. The 
arrows at the top point out active new 
vessels
Figure 9. Ten days after PRP. Note 
regression of new vessels
Fibrovascular 
membrane
Pre-retinal (subhyaloid) 
haemorrhage, covering the 
macula and arcades
Figure 10. Pan-retinal photocoagulation
A
n
t
h
o
n
y
 
H
a
l
l
A
n
t
h
o
n
y
 
H
a
l
l
A
n
t
h
o
n
y
 
H
a
l
l
Active new vessels Fibrovascular membrane 
shows marked resolution
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patient with diabetes, you should 
remember that cataract surgery may 
make diabetic retinopathy worse. 
Eyes with mild to moderate 
non-proliferative diabetic retin-
opathy at the time of surgery are 
considered less at risk. Those with 
severe non-proliferative and prolifer-
ative diabetic retinopathy have a higher 
risk of progressive disease.1 Clinically 
significant macular oedema (CSMO) 
present at the time of surgery is likely to 
progress and eyes with previously treated 
CSMO are at increased risk of recurrence. 
The risk of progression is increased if the 
operation is complicated by excessive 
manipulation, vitreous loss, or severe 
post-operative inflammation.
Ideally, when the cataract does not 
preclude laser treatment, you should 
achieve and maintain 
effective control of retin-
opathy and maculopathy 
for at least three months 
before surgery. 
The severity of the 
cataract sometimes 
prevents adequate 
examination or treatment 
of the retina in patients 
with diagnosed or 
suspected severe 
non-proliferative and proliferative diabetic 
retinopathy. In this case, you should 
deliver pan-retinal photocoagulation 
either during the procedure or in the early 
post-operative period. When performing 
intraoperative pan-retinal photocoagu-
lation with an indirect ophthalmoscope, 
you should fill the anterior chamber with 
viscoelastic and place a corneal suture. 
Complete the pan-retinal photocoagu-
lation before inserting the intraocular 
lens. This will provide a stable anterior 
chamber and optimal view, particularly if 
you anticipate indentation of the periphery.
If you plan to give laser treatment with 
a contact lens in the early post-operative 
period, then you should suture the 
cataract wound. If it is still considered 
hazardous to use a contact lens then 
effective slit lamp laser can still be applied 
through a non-contact 78D or 90D lens. 
You can also use indirect laser for 
pan-retinal photocoagulation.
If the patient has diabetic maculopathy 
and/or more advanced retinopathy, 
consider intravitreal triamcinolone or 
anti-VEGF at the end of the procedure to 
reduce macular oedema. Triamcinolone 
targets the inflammation that exacer-
bates the oedema. Anti-VEGFs also 
reduce retinal swelling and may improve 
visual outcomes.2 Intravitreal steroids 
may cause raised intraocular pressure 
and anti-VEGF agents increase the risk of 
tractional complications in eyes with 
fibrovascular proliferation. You should still 
apply macular laser for CSMO post-opera-
tively.
In diabetes patients, it 
is very important to minimise 
post-operative inflam-
mation. You should use 
post-operative topical 
non-steroidal anti-inflam-
matory drugs in addition 
to routine topical steroid 
preparations, particularly 
in those with pre-existing 
macular oedema.3
In summary, diabetes patients with 
mild to moderate diabetic retinopathy and 
no maculopathy have a good prognosis 
following cataract surgery. You should 
treat more advanced retinopathy or 
maculopathy at least three months prior 
to surgery if possible. Whereas laser is the 
most recognised form of treatment, 
pharmacological agents play an important 
role in the management of these patients. 
It is also important to monitor high-risk 
patients in the post-operative period.
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centre of the exudate. It is not necessary 
to target individual microaneurysms. 
•	Diffuse macular oedema is treated by a 
grid laser in the area of thickening. 
Burns should be one burn width apart, 
using a spot size of 75 to 125 microns, 
duration 20–50 milliseconds. Do not 
use the repeat mode.
•	Start with a low power setting, around 
150 milliwatt, and increase the power 
until the desired endpoint is reached. 
Aim to produce a grey to cream change 
in colour. White means the laser is too 
hot and the power should be reduced. 
•	Take care not to encroach on the foveal 
avascular zone. It is wise to avoid 
treating perifoveal microaneurysms as 
this is likely to increase perifoveal 
capillary dropout (consider intravitreal 
bevacizumab instead). The chorioretinal 
atrophy caused by burns, especially 
intense burns, within 300 to 500 
microns of the fovea can years later 
extend into the fovea and cause vision 
loss, particularly in myopes. 
•	In patients with established foveal 
thickening or who are not responding to 
laser, consider intravitreal bevacizumab. 
In pseudophakic eyes, consider IVTA but 
watch the intraocular pressure closely.
Populations in low- and middle-income 
countries face a huge burden of blinding 
DR. Urgent advocacy is needed for govern-
ments to initiate programmes to address 
this. In the interim, every residency 
programme must provide training in the 
skills needed to manage DR, including 
interpreting investigations and delivering 
laser and other treatments. Refresher 
courses can be arranged for those not 
adequately trained or who have been 
without the necessary equipment for some 
time. We must also advocate for lasers 
and other necessary equipment wherever 
there is a trained ophthalmologist.
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Cataract and diabetic retinopathy
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CATARACT	AnD	DR
‘You should 
remember that 
cataract surgery 
may make diabetic 
retinopathy worse’
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Consider intravitreal triamcinolone or anti-VEGF 
at the end of surgery to reduce macular oedema
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